Eli Lilly Q2 revenue up 48% to $23.0 billion; raises sales outlook, EPS top end cut
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48% from a year earlier, with reported EPS of $7.94, up 26%. The company raised its full-year 2026 revenue guidance to $85.0 billion to $87.0 billion, but its non-GAAP EPS guidance range of $35.50 to $36.50 has a lower top end than the prior $35.50 to $37.00, reflecting $3.03 per share of acquired IPR&D charges from Q2 business development.
Key points
- Q2 2026 revenue rose 48% to $23.0 billion, driven by a 60% increase in volume, partially offset by a 13% decrease in realized prices.
- Reported EPS was $7.94 versus $6.29 a year earlier; non-GAAP EPS was $8.38 versus $6.31.
- Acquired IPR&D charges were $2.8 billion in Q2 2026, compared with $154 million in Q2 2025.
- Full-year 2026 revenue guidance rose to $85.0 billion to $87.0 billion from $82 billion to $85 billion; EPS guidance is now $35.50 to $36.50 from $35.50 to $37.00.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.